支持口服抗癌治疗依从性的干预措施：来自澳大利亚和瑞士的研究挑战、经验教训和克服策略。

Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland.

机构信息

School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Rue Michel Servet 1, 1211, Geneva, Switzerland.

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

出版信息

Support Care Cancer. 2022 May;30(5):3655-3659. doi: 10.1007/s00520-021-06710-y. Epub 2022 Jan 7.

DOI:10.1007/s00520-021-06710-y

PMID:34993650

Abstract

Not monitoring adherence to oral anticancer therapies (OAT) can lead to poor clinical outcomes, including premature death as reported by Foulon et al. (Acta Clin Belg 66(2):85-96, 2011) and Greer et al. (Oncologist 21(3):354-76, 2016). Barriers to the implementation of supportive cancer care interventions in medication adherence occur with multiple hospital sites, cancer diagnoses, and numerous healthcare professionals. This commentary describes challenges and strategies from two OAT adherence trials in Australia and Switzerland to assist researchers in the design and implementation of future interprofessional trials.

摘要

不监测口服抗癌治疗（OAT）的依从性可能导致不良的临床结果，包括过早死亡，这是 Foulon 等人报道的（Acta Clin Belg 66(2):85-96, 2011）和 Greer 等人报道的（Oncologist 21(3):354-76, 2016）。在多个医院、癌症诊断和众多医疗保健专业人员中，支持癌症护理干预措施的实施存在障碍。本评论描述了澳大利亚和瑞士两项 OAT 依从性试验的挑战和策略，以帮助研究人员设计和实施未来的跨专业试验。